Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2020, with a specific reporting date of January 14, 2020. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). The transactions were executed on January 10, 2020, on the London Stock Exchange (XLON) and the New York Stock Exchange (XNYS).
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transaction metrics:
- Instrument Types: Ordinary Shares (25 pence each, ISIN: GB0009252882) and American Depositary Shares (ADSs, ISIN: US37733W1053).
- Transaction Price (Ordinary Shares): GBP 18.0083 per share.
- Transaction Price (ADSs): USD 47.0819 per ADS.
- Transaction Nature: All reported transactions were acquisitions resulting from the re-investment of dividends paid to shareholders on January 9, 2020.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy. It reports routine compliance disclosures regarding the increase in shareholdings of specific executives and their associates due to dividend reinvestment plans. No comparative period data is provided within this document.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory notification of insider trading activity.
Important Facts for Investor Verification
- Dividend Reinvestment: All listed transactions were automatic acquisitions via dividend reinvestment, not open-market purchases initiated by the executives.
- Executive Participation: Key executives participating in the reinvestment include CEO Emma Walmsley, President of Global Vaccines Richard Connor, and CEO of ViiV Healthcare Donna Waterhouse, among others.
- Share Price Consistency: The transaction price was consistent across all Ordinary Share transactions (GBP 18.0083) and all ADS transactions (USD 47.0819) on the execution date.
- Volume Variance: While the price was uniform, the volume of shares acquired varied significantly by individual, ranging from fractional shares to over 2,200 shares (e.g., David Redfern, Chief Strategy Officer).